



Collaboration. Acceleration. Results.

Overview

The Myelin Repair Foundation (MRF) (www.myelinrepair.org) is a Silicon Valley-based, non-profit research organization focused on accelerating the development of myelin repair therapeutics for multiple sclerosis. It is accomplishing this mission by developing and demonstrating a replicable new medical research paradigm to speed treatments for all diseases. In order to achieve its mission, MRF's Accelerated Research Collaboration™ (ARC™) model is designed to coordinate and optimize the entire continuum, from academic medical research to drug development and clinical trials.

In order to advance basic science into clinical trials and drug commercialization, the Myelin Repair Foundation established its rigorous, industry-leading Translational Medicine Platform to drive scientific research to faster, more successful treatments for patients, specifically myelin repair. The MRF Translational Medicine Platform is designed to ensure promising discoveries move rapidly out of the lab and into clinical trials, to ultimately reach the patients.

As part of the Translational Medicine Platform, MRF launched its Translational Medicine Center in late 2011. This state-of-the-art laboratory facility is led by MRF scientists. Together these MRF staff members have over a century of biopharma experience in moving therapeutics to the clinic. The MRF Translational Medicine Center is dedicated to the evaluation of promising myelin research as potential multiple sclerosis therapeutics and the advancement of a wide range of novel myelin reparative therapeutics toward commercialization for multiple sclerosis.

The goal of the MRF is to provide a clear industry pathway from bench to bedside by leveraging its position as a non-partisan, non-profit organization to shorten the time to market for new medicines for patients who can't afford to wait.



MRF scientists at the Translational Medicine Center

Results

- More than 100 potential myelin repair treatment drug targets identified
- Many new tools and assays developed, advancing research for potential multiple sclerosis therapeutics.
- Recipient of seven U.S. patents, thirteen additional applications have been filed in the U.S.
- More than 87 scientific articles and reviews published in peer-reviewed journals
- Extensive relationship building and partnerships and with commercial biopharmaceutical companies
- Launched the MRF Translational Medicine Center and Translational Medicine Platform to translate MRF's research from the lab into new medicines by validating basic discoveries to industry standards.
- Sponsored MRF research has already led to two clinical trials.
- Recognized as one of top 10 most innovative biotech companies by *Fast Company* magazine in 2011 (despite the fact that MRF is a non-profit!)
- The achievements above accomplished for less than \$45M, in less than 8 years

Next Steps...

In order to advance many myelin repair targets forward and accomplish our goal of getting a myelin repair therapeutic to patients in 2019, MRF needs an estimated \$80 million.

About Scott Johnson



Scott Johnson, who has been living with multiple sclerosis for 36 years, is using his acumen as a business consultant and serial entrepreneur to reform a system for medical research and drug development that has failed to produce new patient treatments for millions living with chronic and debilitating diseases.

Scott's ideas and leadership has been recognized by the *Wall Street Journal*, *Forbes*, *New York Times*, *Fast Company*, *The Atlantic*, *Newsweek*, *BusinessWeek* and more. In 2006, he was named as one of Scientific American's top 50 worldwide for business, science and policy leadership. In addition, Scott was recognized as the Northern California Ernst & Young Entrepreneur Of The Year® in the Social Entrepreneurship category in 2010 and received Research!America's 2012 Gordon and Llura Gund Leadership Award.

Defining a New Role for Non-Profits to Accelerate New Treatment Discoveries

The MRF leverages its non-partisan, nonprofit status to connect various entities in the drug discovery continuum in order to achieve a singular goal: shortening the time to discover, validate, conduct trials and get new medicines to patients. The MRF is in a unique position to respond quickly and effectively to drug discovery challenges, identifying the fastest, most effective routes across the gap between academia and the pharmaceutical industry, more commonly known as the "Valley of Death". As a non-profit, the Myelin Repair Foundation's Translational Medicine Platform facilitates improved collaboration between academia, nonprofit organizations and pharma companies to accelerate the development of new patient treatments to the clinic.